



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

July 2023





© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

July 2023

N = 7592



Health Authority	Male	Female	All
FRASER	1523	461	1984
INTERIOR	464	121	585
NORTHERN	149	77	226
VANCOUVER COASTAL	3324	447	3771
VANCOUVER ISLAND	832	167	999
	6292	1273	7565
		Unknown/not stated:	27
		Total:	7592

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (July 2018 - July 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (July 2018 - July 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (July 2018 - July 2023)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (July 2018 - July 2023)






1.6 Percent Distribution of Active Participants by CD4 Count (July 2018 - July 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2018 - July 2023)






1.8 Active and Inactive Participants (July 2018 - July 2023)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (July 2018 - July 2023)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (July 2018 - July 2023)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(July 2018 - July 2023)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (July 2018 - July 2023)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(July 2018 - July 2023)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (July 2018 - July 2023)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(July 2018 - July 2023)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (July 2018 - July 2023)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(July 2018 - July 2023)






1.18 Baseline CD4 for Antiretroviral First Starts (July 2018 - July 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (July 2018 - July 2023)






1.20 Cumulative Resistance Testing Results by Resistance Category (July 2018 - July 2023)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (July 2018 - July 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	31	4	0	4	1	880	4	<40	4
1988	32	4	0	4	1	380	4	<40	4
1989	30	48	1	49	22	500	46	<40	3
1990	28	49	1	50	26	555	48	<40	3
1991	29	37	3	40	17	520	38	<40	3
1992	29	51	3	54	21	680	49	<40	3
1993	28	115	14	129	69	560	123	<40	3
1994	26	67	12	79	42	550	71	<40	3
1995	27	117	18	135	72	560	124	<40	3
1996	24	301	48	349	183	570	319	<40	3
1997	22	261	29	290	158	595	266	<40	3
1998	22	176	38	214	122	585	194	<40	3
1999	22	142	38	180	112	600	164	<40	3
2000	22	115	28	143	77	630	121	<40	3
2001	21	109	24	133	75	620	122	<40	3
2002	20	116	23	139	84	565	130	<40	3
2003	20	131	26	157	95	590	144	<40	3
2004	19	138	38	176	111	650	164	<40	3
2005	18	169	39	208	126	658	187	<40	3
2006	17	164	42	206	116	640	187	<40	3
2007	16	225	41	266	153	640	233	<40	3
2008	15	265	58	323	196	620	289	<40	3
2009	14	289	63	352	206	640	322	<40	3
2010	13	247	66	313	182	675	283	<40	3
2011	12	317	63	380	229	680	341	<40	3
2012	11	253	61	314	174	690	284	<40	3
2013	10	251	65	316	188	690	290	<40	3
2014	9	262	46	308	174	726	281	<40	3
2015	8	258	45	303	167	720	267	<40	3
2016	7	236	49	285	156	680	243	<40	3
2017	6	195	31	226	135	680	203	<40	3
2018	5	177	47	224	134	745	199	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	4	213	40	253	163	690	229	<40	3
2020	3	171	53	224	159	710	204	<40	3
2021	2	178	35	213	128	645	193	<40	3
2022	1	263	49	312	205	670	295	<40	3
2023	0	183	41	224	203	530	218	<40	3
Total:		6297	1278	7575					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1306	620
JUN-2022	7482	759	1839	<40	1201	630
JUL-2022	7495	754	1761	<40	1141	645
AUG-2022	7492	758	1990	<40	1227	620
SEP-2022	7442	772	1787	<40	1091	640
OCT-2022	7468	778	1849	<40	1164	640
NOV-2022	7502	783	1898	<40	1201	630
DEC-2022	7545	787	1607	<40	1004	635
JAN-2023	7583	793	2051	<40	1315	650
FEB-2023	7523	807	1727	<40	1013	630
MAR-2023	7550	803	1974	<40	1208	640
APR-2023	7558	796	1761	<40	1077	630
MAY-2023	7595	786	1933	<40	1208	650
JUN-2023	7607	787	1841	<40	1057	640
JUL-2023	7592	805	1748	<40	1023	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	758	317	60	<40	43	490
JUN-2022	761	291	61	<40	43	400
JUL-2022	764	283	61	<50	36	447
AUG-2022	787	261	59	78	49	560
SEP-2022	844	209	71	<40	53	460
OCT-2022	827	216	83	<40	62	495
NOV-2022	813	213	80	50	60	505
DEC-2022	777	236	57	<40	45	560
JAN-2023	737	289	63	<40	45	550
FEB-2023	790	234	66	<40	53	550
MAR-2023	759	244	78	<40	55	510
APR-2023	762	234	66	<40	47	560
MAY-2023	730	243	65	<40	45	440
JUN-2023	708	213	57	<40	38	445
JUL-2023	734	195	67	<40	49	560

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14485
FEB-2022	7371	856	8	9	151	211	-61	14510
MAR-2022	7432	800	16	9	232	160	61	14539
APR-2022	7397	834	11	1	156	178	-35	14559
MAY-2022	7450	758	13	13	205	146	53	14583
JUN-2022	7457	761	11	15	178	170	7	14620
JUL-2022	7469	764	10	13	188	176	12	14659
AUG-2022	7468	787	15	17	169	172	-1	14697
SEP-2022	7423	844	13	15	146	191	-45	14725
OCT-2022	7443	827	14	16	195	171	20	14760
NOV-2022	7480	813	9	17	210	177	37	14799
DEC-2022	7512	777	19	8	213	166	32	14826
JAN-2023	7552	737	20	10	193	143	40	14861
FEB-2023	7507	790	10	11	159	205	-45	14885
MAR-2023	7534	759	15	21	197	176	27	14919
APR-2023	7536	762	13	13	174	166	2	14948
MAY-2023	7578	730	7	15	203	165	42	14992
JUN-2023	7587	708	13	17	165	157	9	15027
JUL-2023	7575	734	10	12	164	176	-12	15059

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	445	45	7495	8.46%	85.00%	5.94%	0.60%	100.00%
AUG-2022	643	6365	441	43	7492	8.58%	84.96%	5.89%	0.57%	100.00%
SEP-2022	663	6295	439	45	7442	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6309	439	41	7468	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6318	446	42	7502	9.28%	84.22%	5.95%	0.56%	100.00%
DEC-2022	709	6345	449	42	7545	9.40%	84.10%	5.95%	0.56%	100.00%
JAN-2023	721	6373	445	44	7583	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6320	429	39	7523	9.77%	84.01%	5.70%	0.52%	100.00%
MAR-2023	750	6314	445	41	7550	9.93%	83.63%	5.89%	0.54%	100.00%
APR-2023	765	6311	441	41	7558	10.12%	83.50%	5.83%	0.54%	100.00%
MAY-2023	801	6318	435	41	7595	10.55%	83.19%	5.73%	0.54%	100.00%
JUN-2023	821	6307	438	41	7607	10.79%	82.91%	5.76%	0.54%	100.00%
JUL-2023	845	6267	440	40	7592	11.13%	82.55%	5.80%	0.53%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2991 41%	4 11%	2261 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1178 16%	32 86%	4353 59%
SEP-2022	4 14%	2952 40%	3 11%	2195 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2950 40%	4 11%	2173 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2948 40%	5 13%	2158 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2952 40%	3 11%	2149 29%	1 4%	16 0%	18 67%	3446 47%	5 19%	1109 15%	23 85%	4445 60%
JAN-2023	6 17%	2972 40%	1 3%	2148 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1096 15%	29 83%	4466 60%
FEB-2023	3 13%	2945 40%	1 4%	2098 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1066 14%	21 88%	4447 60%
MAR-2023	2 6%	2937 40%	2 6%	2072 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1052 14%	32 94%	4477 60%
APR-2023	3 10%	2951 40%	1 3%	2070 28%	0 0%	15 0%	24 83%	3551 48%	3 10%	1031 14%	26 90%	4471 60%
MAY-2023	10 24%	2942 39%	4 10%	2045 27%	1 2%	16 0%	30 71%	3599 48%	3 7%	1041 14%	32 76%	4515 61%
JUN-2023	4 12%	2936 39%	1 3%	2010 27%	0 0%	14 0%	26 76%	3658 49%	4 12%	1005 13%	30 88%	4539 61%
JUL-2023	5 16%	2923 39%	1 3%	1971 26%	0 0%	14 0%	25 78%	3682 49%	3 9%	990 13%	27 84%	4539 61%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	385 26%	1 100%	1028 71%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	367 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	354 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	342 25%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	994 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	954 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	0 0%	0 0%	317 24%	1 100%	953 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	0 0%	0 0%	305 23%	1 100%	959 74%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	0 0%	0 0%	304 23%	2 100%	953 74%	0 0%	40 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	0 0%	0 0%	296 23%	0 0%	938 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	0 0%	0 0%	284 23%	3 100%	929 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	183 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 26%	0 0%	197 19%
DEC-2022	0 0%	186 19%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	225 24%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	2 100%	224 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir															
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All														
JAN-2022	11	73%	2421	43%	0	0%	0	0%	2	13%	2468	44%	1	7%	347	6%	0	0%	0	0%	0	0%	24	0%	1	7%	374	7%
FEB-2022	15	71%	2443	44%	0	0%	0	0%	6	29%	2437	44%	0	0%	331	6%	0	0%	0	0%	0	0%	21	0%	0	0%	369	7%
MAR-2022	23	85%	2536	45%	0	0%	0	0%	3	11%	2460	43%	1	4%	324	6%	0	0%	0	0%	0	0%	21	0%	0	0%	370	7%
APR-2022	14	74%	2574	45%	0	0%	0	0%	5	26%	2436	43%	0	0%	312	5%	0	0%	0	0%	0	0%	20	0%	0	0%	366	6%
MAY-2022	17	77%	2666	46%	0	0%	0	0%	5	23%	2455	43%	0	0%	309	5%	0	0%	0	0%	0	0%	22	0%	0	0%	360	6%
JUN-2022	29	85%	2710	47%	0	0%	0	0%	5	15%	2454	42%	0	0%	300	5%	0	0%	0	0%	0	0%	22	0%	0	0%	352	6%
JUL-2022	24	69%	2745	47%	0	0%	0	0%	7	20%	2452	42%	3	9%	297	5%	0	0%	0	0%	0	0%	22	0%	1	3%	342	6%
AUG-2022	26	76%	2790	48%	0	0%	0	0%	6	18%	2452	42%	1	3%	294	5%	0	0%	0	0%	1	3%	22	0%	1	3%	340	6%
SEP-2022	19	76%	2820	48%	0	0%	0	0%	6	24%	2433	42%	0	0%	281	5%	0	0%	0	0%	0	0%	21	0%	0	0%	323	6%
OCT-2022	28	80%	2889	49%	0	0%	0	0%	6	17%	2440	41%	1	3%	280	5%	0	0%	0	0%	0	0%	22	0%	0	0%	314	5%
NOV-2022	24	73%	2920	49%	0	0%	0	0%	8	24%	2462	41%	1	3%	276	5%	0	0%	1	0%	0	0%	22	0%	0	0%	309	5%
DEC-2022	16	70%	2974	50%	0	0%	0	0%	5	22%	2465	41%	1	4%	270	4%	0	0%	1	0%	0	0%	20	0%	1	4%	307	5%
JAN-2023	23	82%	3016	50%	0	0%	0	0%	5	18%	2493	41%	0	0%	269	4%	0	0%	1	0%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040	50%	0	0%	0	0%	6	25%	2477	41%	0	0%	255	4%	0	0%	1	0%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084	51%	0	0%	0	0%	5	15%	2483	41%	2	6%	259	4%	0	0%	1	0%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3085	50%	0	0%	0	0%	4	15%	2499	41%	1	4%	258	4%	0	0%	1	0%	0	0%	18	0%	0	0%	275	5%
MAY-2023	28	67%	3139	51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	1	0%	0	0%	18	0%	0	0%	279	5%
JUN-2023	26	81%	3199	51%	0	0%	5	0%	6	19%	2510	40%	0	0%	249	4%	0	0%	1	0%	0	0%	18	0%	0	0%	268	4%
JUL-2023	25	83%	3221	52%	0	0%	5	0%	5	17%	2502	40%	0	0%	248	4%	0	0%	1	0%	0	0%	18	0%	0	0%	258	4%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	828	11.05	691	9.22	4610	61.53	641	8.56	648	8.65	74	0.99
SEP-2022	799	10.74	691	9.29	4575	61.48	662	8.90	641	8.61	74	0.99
OCT-2022	788	10.55	673	9.01	4620	61.86	678	9.08	636	8.52	73	0.98
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	645	8.60	72	0.96
DEC-2022	774	10.26	663	8.79	4681	62.04	706	9.36	650	8.61	71	0.94
JAN-2023	751	9.90	665	8.77	4729	62.36	718	9.47	648	8.55	72	0.95
FEB-2023	716	9.52	665	8.84	4713	62.65	733	9.74	625	8.31	71	0.94
MAR-2023	700	9.27	653	8.65	4736	62.73	748	9.91	643	8.52	70	0.93
APR-2023	706	9.34	653	8.64	4738	62.69	762	10.08	634	8.39	65	0.86
MAY-2023	709	9.34	644	8.48	4753	62.58	799	10.52	626	8.24	64	0.84
JUN-2023	679	8.93	626	8.23	4792	62.99	819	10.77	626	8.23	65	0.85
JUL-2023	666	8.77	628	8.27	4766	62.78	843	11.10	627	8.26	62	0.82

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	13	1	3	1	1	5	440
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	12	1	2	4	2	3	265

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12277	3734
FEB-2022	12300	3748
MAR-2022	12328	3763
APR-2022	12357	3788
MAY-2022	12348	3777
JUN-2022	12363	3779
JUL-2022	12389	3788
AUG-2022	12410	3800
SEP-2022	12429	3809
OCT-2022	12455	3829
NOV-2022	12463	3819
DEC-2022	12440	3801
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12443	3787
APR-2023	12418	3753
MAY-2023	12426	3731
JUN-2023	12400	3693
JUL-2023	12428	3716

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7592
Jul-2023

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jul-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	45	61	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	101	53	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	441	599	329	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	235	318	175	
Total HA:		794	1079	585

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		794	1079	585

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	163	221	121
Male	631	858	464

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	585	56	670	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	24	14
	5 years or more	15	8
	<5 years	6	6
	Total HSDA:	45	28
KOOTENAY BOUNDARY	10 years or more	48	32
	5 years or more	13	10
	<5 years	12	11
	Total HSDA:	73	53
OKANAGAN	10 years or more	280	207
	5 years or more	88	65
	<5 years	73	57
	Total HSDA:	441	329
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	145	109
	5 years or more	45	30
	<5 years	45	36
	Total HSDA:	235	175
Total HA:		794	585

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	497	362
5 years or more	161	113
<5 years	136	110
Total HA:	794	585

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	52	70	11	13
KOOTENAY BOUNDARY	79	138	19	42
OKANAGAN	239	1086	52	339
THOMPSON/CARIBOO/SHUSWAP	150	569	33	143
Total:	520	1863	115	537

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	12
KOOTENAY BOUNDARY	12
OKANAGAN	70
THOMPSON/CARIBOO/SHUSWAP	48
Total:	142

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	38	40	31
	35-49	100	102	66
	50+	267	371	196
	Total HSDA:	412	520	298
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1150	1558	868
FRASER SOUTH	0-19	9	9	9
	20-34	109	111	79
	35-49	301	327	235
	50+	626	959	495
	Total HSDA:	1045	1406	818
Total HA:		2607	3484	1984

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	15
	20-34	285	290	207
	35-49	762	816	575
	50+	1543	2361	1187
Total HA:		2607	3484	1984

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	631	807	461
Male	1976	2677	1523

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1984	53	658	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	279	207
	5 years or more	63	35
	<5 years	70	56
	Total HSDA:	412	298
FRASER NORTH	10 years or more	715	518
	5 years or more	239	188
	<5 years	196	162
	Total HSDA:	1150	868
FRASER SOUTH	10 years or more	642	493
	5 years or more	209	160
	<5 years	194	165
	Total HSDA:	1045	818
Total HA:		2607	1984

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1636	1218
	5 years or more	511	383
	<5 years	460	383
Total HA:		2607	1984

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	150	542	31	62
FRASER NORTH	261	1627	43	222
FRASER SOUTH	227	1809	48	488
Total:	638	3978	122	772

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	202
FRASER NORTH	713
FRASER SOUTH	473
Total:	1388

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		354	526
RICHMOND	20-34	29	30	18
	35-49	61	62	48
	50+	120	176	97
	Total HSDA:	210	268	163
VANCOUVER	0-19	13	13	12
	20-34	446	460	301
	35-49	1235	1376	876
	50+	2992	5349	2143
	Total HSDA:	4686	7198	3332
Total HA:		5250	7992	3771

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	13
	20-34	504	519	336
	35-49	1368	1517	978
	50+	3364	5942	2444
Total HA:		5250	7992	3771

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	595	969	447
Male	4653	7021	3324
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3771	55	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	243	193
	5 years or more	54	44
	<5 years	57	39
	Total HSDA:	354	276
RICHMOND	10 years or more	125	94
	5 years or more	37	27
	<5 years	48	42
	Total HSDA:	210	163
VANCOUVER	10 years or more	3271	2255
	5 years or more	792	577
	<5 years	623	500
	Total HSDA:	4686	3332
Total HA:		5250	3771

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3639	2542
5 years or more	883	648
<5 years	728	581
Total HA:	5250	3771

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	188	417	39	52
RICHMOND	45	316	8	96
VANCOUVER	688	11746	216	5455
Total:	921	12479	263	5603

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	69

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		357	523
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		129	181
SOUTH VANCOUVER ISLAND	20-34	68	74	45
	35-49	195	219	148
	50+	546	870	420
	Total HSDA:	809	1163	613
Total HA:		1295	1867	999

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1295	1867	999

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	216	316	167
Male	1079	1551	832

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	999	56	600	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	221	177
	5 years or more	74	49
	<5 years	62	55
	Total HSDA:	357	281
NORTH VANCOUVER ISLAND	10 years or more	92	75
	5 years or more	24	18
	<5 years	13	12
	Total HSDA:	129	105
SOUTH VANCOUVER ISLAND	10 years or more	501	368
	5 years or more	158	122
	<5 years	150	123
	Total HSDA:	809	613
Total HA:		1295	999

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	814	620
	5 years or more	256	189
	<5 years	225	190
Total HA:		1295	999

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	204	931	68	169
NORTH VANCOUVER ISLAND	160	285	39	71
SOUTH VANCOUVER ISLAND	225	1951	38	589
Total:	589	3167	145	829

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	109
NORTH VANCOUVER ISLAND	45
SOUTH VANCOUVER ISLAND	124
Total:	278

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	5
	35-49	16	20	12
	50+	29	37	15
	Total HSDA:	53	65	32
NORTH WEST	20-34	*	5	0
	35-49	*	38	17
	50+	*	77	34
	Total HSDA:	72	120	51
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	198	298	143
Total HA:		323	483	226

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		323	483	226

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	176	77
Male	208	307	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	226	53	570	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	6	*
	<5 years	16	*
	Total HSDA:	53	32
NORTH WEST	10 years or more	51	34
	5 years or more	11	9
	<5 years	10	8
	Total HSDA:	72	51
NORTHERN INTERIOR	10 years or more	109	80
	5 years or more	54	38
	<5 years	35	25
	Total HSDA:	198	143
Total HA:		323	226

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	191	128
	5 years or more	71	50
	<5 years	61	48
Total HA:		323	226

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	41	61	6	8
NORTH WEST	88	181	16	40
NORTHERN INTERIOR	123	506	24	191
Total:	252	748	46	239

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	5
NORTH WEST	21
NORTHERN INTERIOR	14
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	9	*
	OKANAGAN	*	52	*
	THOMPSON/CARIBOO/SHUSWAP	*	51	*
	Total HA:	67	122	47
FRASER	FRASER EAST	37	52	29
	FRASER NORTH	51	94	38
	FRASER SOUTH	79	116	52
	Total HA:	167	262	119
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	52	24
	RICHMOND	6	11	5
	VANCOUVER	455	910	368
	Total HA:	486	973	397
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	82	39
	NORTH VANCOUVER ISLAND	15	29	12
	SOUTH VANCOUVER ISLAND	49	96	40
	Total HA:	111	207	91
NORTHERN	NORTH EAST	10	14	5
	NORTH WEST	32	68	20
	NORTHERN INTERIOR	72	120	53
	Total HA:	114	202	78
Total:		945	1766	732

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	345	632	271
Male	600	1134	461

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	732	54	540	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Monthly Report

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





Monthly Report

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Monthly Report

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

